Beyond the Averages: The Hidden Crisis in Patient Access to Care

SAN FRANCISCO, CA – July 28, 2026

A new report released today paints a seemingly reasonable picture of patient access to critical medications. The data, from AI-powered platform SamaCare, shows that prior authorizations for medical benefit drugs have a 76.5% average net approval rate and are resolved in about two days. On the surface, these figures suggest a system that, while not perfect, is largely functional. But to accept these averages at face value is to ignore the fractured, frustrating, and often harmful reality faced by millions of patients and their providers.

The true story, buried beneath the aggregate numbers, is one of profound variability. SamaCare's Q2 2026 Market Access Benchmarks reveal a healthcare landscape where a patient’s ability to get a prescribed therapy depends less on medical necessity and more on a chaotic lottery of their specific diagnosis, their doctor's specialty, their insurance provider, and even the formulation of their medication. This isn't a system with minor inefficiencies; it's a labyrinth of administrative barriers where averages conceal the deep chasms into which patient care can fall.

The Anatomy of Delay

Dissecting the data reveals just how misleading a national average can be. The journey from prescription to treatment is fraught with specific, predictable friction points. According to the new analysis, which covers thousands of practices nationwide, a patient's very first attempt to start a new therapy is one of the most significant hurdles. Across most medical specialties, prior authorizations for therapy continuations saw higher approval rates than those for initiations. This suggests that while payers may be willing to keep patients on a treatment they've already approved, getting that first 'yes' is a significant battle. The one exception noted was in Retina, where initiation approvals slightly outpaced continuations, a curious anomaly in an otherwise consistent trend of gatekeeping at the outset of care.

The complexity of the therapy itself adds another layer of unpredictability. The report highlights that specialty biologics, biosimilars, and immunoglobulin therapies demonstrate far greater variability in approval performance. Even within an established brand, a simple change in delivery—such as a new subcutaneous formulation—can trigger a completely different and often more arduous access pathway. This forces pharmaceutical companies and providers to track performance not just at the brand level, but for each individual product and formulation.

"Average prior authorization performance only tells part of the story," noted Syam Palakurthy, Founder and CEO of SamaCare, in the press release. "For market access teams, the real question is where access breaks down, for which patients, in which specialties, and under which payer workflows." The data shows that even the same drug can face wildly different approval rates depending on the insurer, a clear signal that payer policy interpretation and internal operating models are powerful, often arbitrary, determinants of patient care.

The Human Cost of Administrative Hurdles

While the data provides a clinical map of these access barriers, the consequences are deeply human. For providers, the prior authorization process has become a leading source of burnout and a colossal drain on resources. According to a 2024 American Medical Association (AMA) survey, physicians and their staff spend an average of 13 hours per week completing these forms. One practice manager confessed, "We have staff members who do nothing else. They are professional navigators of a system designed to be difficult."

This administrative sludge isn't just an inconvenience; it has dire clinical consequences. The same AMA survey found that 93% of physicians report prior authorization requirements delay patient care, with nearly a third (29%) stating that these delays have led to a serious adverse event for a patient, including hospitalization, permanent disability, or death. The psychological toll on patients waiting for a life-altering medication is immense, and for many, the delays prove insurmountable. An astonishing 79% of patients are reported to simply abandon their prescribed treatment when faced with an arduous authorization process.

These delays and denials don't just harm patients; they paradoxically increase costs. Contrary to the payer argument that prior authorization controls spending, 88% of physicians report that the process ultimately leads to higher overall healthcare utilization, as delays result in disease progression, additional office visits, and more expensive emergency interventions.

A Fractured System of Payers and Policies

The root cause of this variability is a fundamental lack of standardization. With no universal commercial plan standards for prior authorization, providers are forced to navigate a dizzying array of unique rules, forms, and submission portals for each payer. This fragmentation creates a system ripe for error, delay, and inequity.

SamaCare's analysis of payer-level performance puts this disparity in stark relief. While the median time to resolution across all payer-specialty combinations was approximately 2.1 days, the slowest 10% of these combinations took an average of more than 8.8 days to render a decision. For a patient with a rapidly progressing condition, that extra week is an eternity. This is the tangible impact of disparate payer policies, documentation requirements, and operational inefficiencies. A provider in Ohio treating a patient with a chronic inflammatory disease may face a completely different set of hurdles than a provider in California prescribing the exact same medication to a patient with the same diagnosis.

As Palakurthy stated, "Medical benefit access is not one national average. There are thousands of local workflows happening across therapies, providers, payers, plans, and sites of care." Recognizing and measuring this variation is the first step toward dismantling the arbitrary barriers that stand between a prescription and a patient.

The Double-Edged Sword of Innovation

In response to this crisis, a new generation of institutional innovation is emerging. Technology platforms like SamaCare, Waystar, and Cohere Health are leveraging AI and vast datasets to bring transparency and efficiency to this opaque process. By automating submissions, providing pre-submission policy intelligence, and analyzing real-world data, these tools aim to streamline workflows for providers. The results are promising; SamaCare’s own data shows that its manufacturer-sponsored intervention programs have slashed resolution times by 84% and cut denial rates by 42% compared to the baseline.

Regulators are also taking notice. The Centers for Medicare & Medicaid Services (CMS) has finalized rules, effective this year, mandating electronic prior authorization and stricter decision timelines for Medicare Advantage and other plans. A proposed rule for 2026 aims to extend these protections to medical benefit drugs, potentially requiring decisions within 72 hours for standard requests and mandating that payers provide specific reasons for denials.

However, this technological arms race is a double-edged sword. While provider-facing AI can empower practices to submit cleaner, faster requests, physician advocacy groups like the AMA have raised alarms about payers deploying their own AI to review claims. The fear is that these algorithms could be used to issue "systematic batch denials" without adequate human oversight, creating an even more formidable and impersonal barrier to care. The challenge, then, is not just to innovate, but to ensure that innovation serves the patient, not the process.